alemtuzumab-induced immune suppression might be related with these fatal outcomes. In this study, myelosuppression and infectious complications including CMV reactivation were the major toxic effects, and these are similar to previous studies with alemtuzumab [1, 3, 4] . Alemtuzumab is known to suppress immunity including the depletion of CD4 and CD8 T cells as well as B cells [5] . Thus, this alemtuzumab-induced B-cell and T-cell depletion might last longer than expected, and it might result in serious adverse events in this study. Therefore, because of a substantial incidence of serious adverse events, we modified the 
